Year : 2017  |  Volume : 11  |  Issue : 2  |  Page : 232-235

A case report of suspected malignant hyperthermia where patient survived the episode

Department of Anaesthesiology and Critical Care, SMHS Hospital, GMC, Srinagar, Jammu and Kashmir, India

Correspondence Address:
Asif Iqbal
36, Ram Bagh Extension, Near Noorani Masjid, Srinagar - 190 015, Jammu and Kashmir
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1658-354X.203057

Rights and Permissions

Malignant hyperthermia is rare inherited disorder in our part of the world; there are only few cases reported in literature in India who were suspected of having this condition. The overall incidence of malignant hyperthermia during general anesthesia is estimated to range from 1: 5000 to 1: 50,000–100,000 and mortality rate is estimated to be <5% in the presence of standard care. In India, there is no center where in vitro halothane caffeine contraction test is performed to confirm diagnosis in suspected cases. Second, dantrolene drug of choice for this condition is not freely available in market in India and is stored only in some hospitals in few major cities. Among the cases reported of suspected of malignant hyperthermia in India almost 50% have survived the condition despite nonavailability of dantrolene emphasizing role of early detection and aggressive management in these cases.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded200    
    Comments [Add]    
    Cited by others 1    

Recommend this journal